6-MERCAPTOPURINE PLASMA-LEVELS IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - RELATION TO RELAPSE RISK AND MYELOTOXICITY

被引：44
作者：
HAYDER, S
LAFOLIE, P
BJORK, O
PETERSON, C
机构：
[1] KAROLINSKA HOSP,DEPT CLIN PHARMACOL,POB 60500,S-10401 STOCKHOLM 60,SWEDEN
[2] KAROLINSKA HOSP,DEPT PEDIAT,S-10401 STOCKHOLM 60,SWEDEN
来源：
THERAPEUTIC DRUG MONITORING | 1989年 / 11卷 / 06期
关键词：
D O I：
10.1097/00007691-198911000-00001
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：617 / 622
页数：6
相关论文
共 50 条
  • [41] Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia
    Singh, Minu
    Bhaskar, Divya
    Bhatia, Prateek
    Thakur, Rozy
    Sharma, Pankaj
    Bansal, Deepak
    Jain, Richa
    Trehan, Amita
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (01) : 51 - 56
  • [42] INFLUENCE OF CRANIAL IRRADIATION (CI) ON CEREBRAL SPINAL-FLUID (CSF) LEVELS OF 6-MERCAPTOPURINE (6-MP) IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL)
    RICCARDI, R
    RICCARDI, A
    LASORELLA, A
    SERVIDEI, T
    TARTAGLIA, RL
    MASTRANGELO, R
    MEDICAL AND PEDIATRIC ONCOLOGY, 1987, 15 (06): : 341 - 341
  • [43] Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia
    Rikke Hebo Larsen
    Lisa Lyngsie Hjalgrim
    Kathrine Grell
    Kim Kristensen
    Line Gerner Pedersen
    Emilie Damgaard Brünner
    Bodil Als-Nielsen
    Kjeld Schmiegelow
    Jacob Nersting
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 25 - 32
  • [44] Isolated decrease of factor v in children treated by 6-mercaptopurine for acute lymphoblastic leukemia
    Filhon, B.
    Dumesnil, C.
    Van Dreden, P.
    Compagnon, P.
    Adam, M.
    Schneider, P.
    Vasse, M.
    Vannier, J. P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 471 - 472
  • [45] Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
    Relling, MV
    Hancock, ML
    Boyett, JM
    Pui, CH
    Evans, WE
    BLOOD, 1999, 93 (09) : 2817 - 2823
  • [46] PROGNOSTIC-SIGNIFICANCE OF METHOTREXATE AND 6-MERCAPTOPURINE DOSAGE DURING MAINTENANCE CHEMOTHERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    SCHMIEGELOW, K
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1991, 8 (04) : 301 - 312
  • [47] IMMUNOPHENOTYPIC CHANGES IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) AT RELAPSE
    DOWELL, BL
    MAHONEY, DH
    STEUBER, CP
    FERNBACH, DJ
    LEUKEMIA, 1987, 1 (03) : 279 - 279
  • [48] PHYSICIAN COMPLIANCE AND RELAPSE RATES OF ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDREN
    PEETERS, M
    KOREN, G
    JAKUBOVICZ, D
    ZIPURSKY, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (03) : 228 - 232
  • [49] RISK OF RELAPSE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA IS RELATED TO RBC METHOTREXATE AND MERCAPTOPURINE METABOLITES DURING MAINTENANCE CHEMOTHERAPY
    SCHMIEGELOW, K
    SCHRODER, H
    GUSTAFSSON, G
    KRISTINSSON, J
    GLOMSTEIN, A
    SALMI, T
    WRANNE, L
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (02) : 345 - 351
  • [50] Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine
    Erb, N
    Harms, DO
    Janka-Schaub, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (04) : 266 - 272
12345